Analyst Expectations for Milestone Pharmaceuticals's Future
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 5 analysts have published their opinion on Milestone Pharmaceuticals (NASDAQ:MIST) stock, with an average 12-month price target of $18.4, up 53.33% from the previous average of $12. The company has received 3 bullish, 1 somewhat bullish, and 1 indifferent rating.

June 20, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Milestone Pharmaceuticals (NASDAQ:MIST) has an average 12-month price target of $18.4, up 53.33% from the previous average, with 3 bullish, 1 somewhat bullish, and 1 indifferent rating from 5 analysts.
The average 12-month price target for MIST has increased by 53.33% from the previous average, indicating a positive outlook from analysts. With 3 bullish, 1 somewhat bullish, and 1 indifferent rating, the overall sentiment is positive, which could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100